A Multicenter, Randomized, Open-label Phase II Clinical Trial Evaluating Alprostadil Liposomal Injection in the Prevention of Contrast-induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Alprostadil (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 21 Nov 2024 Status changed from recruiting to discontinued.
- 26 Oct 2022 Status changed from not yet recruiting to recruiting.
- 01 Aug 2022 New trial record